Theme Edition 2016

International R&D Meeting
“Neurosciences, Neurology and Psychiatry”
Paris, November 3rd, 2016
Rationnel 2016


RIR to foster public-private partnership. Public and private partnerships are essential to foster innovation in health industries. Since the launch in 2009 of the first International R&D Meetings, a great number of companies committed themselves to develop private-public partnerships. Aligned with this main strategic objective, ARIIS in cooperation with the Institute of Neurosciences, Cognitive Sciences, Neurology and Psychiatry of Aviesan (the French national Alliance for life sciences and health) organizes the 7th International R&D Meeting on November 3rd, 2016.

The burden of brain/mental disorders. Substantial proportion of the world’s health problems now arises from mental, neurological, and substance use disorders. This burden is emotional, financial and social to the patients, their families, and their social network. In Europe, the total cost (direct and indirect) has been estimated at € 798 billions in 2010.

Neurologic and mental health disorders share common mechanisms.
Neurological disorders are characterized by neural cell degeneration including Alzheimer disease and related dementias, Parkinson’s disease, multiple sclerosis, and cerebrovascular diseases (stroke), or neuronal dysfunction including epilepsy, migraine and other headache disorders among other. Mental disorders include a wide range of disorders such as anxiety disorders, obsessive-compulsive disorder, bipolar disorder, depression, mood disorders, autism, personality disorders, schizophrenia. Large body of evidence indicates that neurologic and psychiatric disorders share common biological alterations of the nervous system opening the possibility to develop common therapeutic strategies.

The challenges. A lot remains to be done. There is need to better characterize the diseases using preclinical studies and better define them clinically for stratification purposes. The current challenge is the identification of specific biomarkers (including behavioral ones) permitting early diagnosis, disease prevention, drug target identification, drug response, drug toxicity etc.

French public organization of research in Neuroscience, Neurology and Psychiatry: many opportunities to foster private-public partnership. Most of the research laboratories involved in neurologic and psychiatric disorders are localized on or very close to medical campus to facilitate translational research from bench to bed side. Centers and networks of expert centers exist for specific disorders such as dementia, Parkinson disease, multiple sclerosis, epilepsy, behavior disorders, autism and schizophrenia. Such an organization relies also on the centers for clinical investigation Network, which provide the methodological expertise and allow inter-operability across the country. This organization and governmental “investment for the future” funding allowed creation of an exceptional ecosystem favoring translational research, large cohorts of well characterized patients, biobanks, imaging facilities, data repositories. The French government has highlighted its priority for brain diseases by launching 2 plans the “Plan Maladies neurodégénératives 2014-2019” and the “Plan Autisme 2013-2017”.

The 7th edition of the R&D meeting will cover, through selected presentations of top French experts, and face to face meeting, these aspects with the aim to facilitate and stimulate interactions between academic laboratories, networks of clinicians/biologists and industrial partners. The topics will include presentation the existing cohorts for brain disorders, the identification of biomarkers to stratify patients and provide an individual adapted treatments, tools to follow the evolution of neurodegenerative disorders and the prediction of treatment efficacy, translational research facilities and the new technologies including modern imaging, big data management, brain delivery tools, brain machine interface, serious games and other methods to improve brain functions.